Inorial

Bilastine, the active ingredient in Inorial, is a second‑generation H1 antihistamine presented as an ocular solution for eye use. It alleviates symptoms of allergic conjunctivitis and ocular itching caused by environmental allergens in patients of all ages.

GNH USA supplies Inorial as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution. The company ensures product integrity through rigorous quality control and regulatory oversight.

Inorial (bilastine) is used to treat ocular allergic conditions by blocking peripheral H1 receptors. - Allergic conjunctivitis: reduces redness, swelling and itching caused by allergic triggers. - Seasonal allergic conjunctivitis: provides relief during pollen or mold exposure periods. - Ocular itching due to allergy: diminishes the urge to rub or scratch the eyes, improving comfort.

Bilastine may cause ocular and systemic adverse reactions, which are categorized by frequency.

Common Side Effects: - Transient eye irritation or burning sensation. - Bitter taste after instillation. - Mild headache. - Dry eye sensation.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) with swelling of the face or throat. - Vision changes such as blurred vision or photophobia. - Persistent ocular edema. - Acute angle‑closure glaucoma (rare).

When prescribing Inorial, consider the following precautions to ensure safe use. - Assess hypersensitivity: confirm no known allergy to bilastine or similar antihistamines. - Monitor ocular irritation: advise patients to report persistent burning or redness. - Caution in hepatic impairment: use with care if liver function is compromised. - Avoid use in children under 2 years: safety not established for this age group. - Store at room temperature: keep in the original container, protect from moisture and light.

Bilastine can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Concurrent use with other H1 antihistamine eye drops: may increase risk of additive ocular irritation. - Co‑administration with systemic antihistamines that cause sedation: may enhance drowsiness.

Moderate Interactions (Monitor Closely): - Potent CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic exposure, requiring monitoring. - Alcohol consumption: can potentiate mild central nervous system effects. - Other ocular vasoconstrictors: may increase local irritation or pressure. - Anticholinergic agents: may augment dry eye symptoms.